The EMJ Podcast | Bonus Episode
This content has been funded by medac.
Spotify | Apple | Amazon Music | Download MP3 (27:41 mins)
In this new insightful podcast, expert in oncological urology Fred Witjes, Radboud University, Nijmegen, the Netherlands, sits down to discuss management of the side effects that follow Bacillus Calmette-Guérin (BCG). Witjes dives into the absolute and relative contraindications for BCG instillation, and explores some of the real-world reasons for BCG treatment discontinuation, before delving into signs that clinicians should look out for in their patients, and the procedures they can follow to reduce adverse events after BCG.1-5
Other topics discussed include:
- Reducing the rate of lower urinary tract symptoms-related BCG treatment discontinuation
- How to increase the confidence of urologists regarding BCG side effect management
- How to make adequate use of the major drug classes used in the management of BCG side effects
- When healthcare professionals should make the call to switch treatments
Speaker
Fred Witjes1
1. Radboud University, Nijmegen, the Netherlands
References
1. European Association of Urology (EAU). EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). 2024. Available at: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer. Last accessed: 4 November 2024.
2. Koch GE et al. Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them. Urology. 2021;149:11-20. Available at: https://www.goldjournal.net/article/S0090-4295(20)31349-2/abstract. Last accessed: 4 November 2024.
3. Larsen ES et al. The epidemiology of bacille Calmette-Guérin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int. 2019;124(6):910-6. Available at: https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.14793. Last accessed: 4 November 2024.
4. Holmberg L et al. Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations. BJU Int. 2024;134(2):229-38. Available at: https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.16303. Last accessed: 4 November 2024.
5. Witjes JA et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl. 2008;10(7):667-674. Available at: https://www.eu-openscience.europeanurology.com/article/S1569-9056(08)00110-3/fulltext.
2. Koch GE et al. Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them. Urology. 2021;149:11-20. Available at: https://www.goldjournal.net/article/S0090-4295(20)31349-2/abstract. Last accessed: 4 November 2024.
3. Larsen ES et al. The epidemiology of bacille Calmette-Guérin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int. 2019;124(6):910-6. Available at: https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.14793. Last accessed: 4 November 2024.
4. Holmberg L et al. Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations. BJU Int. 2024;134(2):229-38. Available at: https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.16303. Last accessed: 4 November 2024.
5. Witjes JA et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl. 2008;10(7):667-674. Available at: https://www.eu-openscience.europeanurology.com/article/S1569-9056(08)00110-3/fulltext.
